Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application
Shuai Wang, Xiaohan Yuan, Saiqi Wang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 214, pp. 113218-113218
Closed Access | Times Cited: 99

Showing 1-25 of 99 citing articles:

Recent studies of nitrogen containing heterocyclic compounds as novel antiviral agents: A review
Arif Mermer, Turgut Keleş, Yakup Şirin
Bioorganic Chemistry (2021) Vol. 114, pp. 105076-105076
Closed Access | Times Cited: 239
The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design
Yong Ling, Zhi‐You Hao, Dong Liang, et al.
Drug Design Development and Therapy (2021) Vol. Volume 15, pp. 4289-4338
Open Access | Times Cited: 235
Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism
Mohammed A. S. Abourehab, Alaa M. Alqahtani, Bahaa G. M. Youssif, et al.
Molecules (2021) Vol. 26, Iss. 21, pp. 6677-6677
Open Access | Times Cited: 122
Recent Advances in Pyridine Scaffold: Focus on Chemistry, Synthesis, and Antibacterial Activities
Md. Badrul Islam, Md. Inshaful Islam, Nikhil Nath, et al.
BioMed Research International (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 49
Hydrazide-hydrazone/hydrazone as enabling linkers in anti-cancer drug discovery: A comprehensive review
Solai Murugappan, Sowmya Dastari, Kalyani Jungare, et al.
Journal of Molecular Structure (2024) Vol. 1307, pp. 138012-138012
Closed Access | Times Cited: 17
Small-molecule MDM2 inhibitors in clinical trials for cancer therapy
Shuai Wang, Fen‐Er Chen
European Journal of Medicinal Chemistry (2022) Vol. 236, pp. 114334-114334
Closed Access | Times Cited: 61
CDK inhibitors from past to present: A new wave of cancer therapy
Muhammad Jameel, Kinjal Bhadresha, Hang Fai Kwok
Seminars in Cancer Biology (2022) Vol. 88, pp. 106-122
Open Access | Times Cited: 52
Recent advances in nitrogen-containing heterocyclic compounds as receptor tyrosine kinase inhibitors for the treatment of cancer: Biological activity and structural activity relationship
Keshav Taruneshwar Jha, Abhimannu Shome, Chahat, et al.
Bioorganic Chemistry (2023) Vol. 138, pp. 106680-106680
Closed Access | Times Cited: 26
Polyoxometalate catalysts for the synthesis of N-heterocycles
Qi-Long Hu, Ke Li, Xuejiao Chen, et al.
Polyoxometalates (2023) Vol. 3, Iss. 1, pp. 9140048-9140048
Open Access | Times Cited: 26
Antioxidant activity of novel nitrogen scaffold with docking investigation and correlation of DFT stimulation
Mona A. Shalaby, Asmaa M. Fahim, Sameh A. Rizk
RSC Advances (2023) Vol. 13, Iss. 21, pp. 14580-14593
Open Access | Times Cited: 24
Current scenario of pyrazole hybrids with in vivo therapeutic potential against cancers
Zhi Xu, Yafei Zhuang, Qingtai Chen
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115495-115495
Closed Access | Times Cited: 24
N-Heterocycles as Promising Antiviral Agents: A Comprehensive Overview
Gulraız Ahmad, Maria Sohail, Muhammad Bılal, et al.
Molecules (2024) Vol. 29, Iss. 10, pp. 2232-2232
Open Access | Times Cited: 7
Structural modification strategies of triazoles in anticancer drug development
Qianwen Guan, Ziming Gao, Yuting Chen, et al.
European Journal of Medicinal Chemistry (2024) Vol. 275, pp. 116578-116578
Closed Access | Times Cited: 6
Pyrimidine-based dual-target inhibitors targeting epidermal growth factor receptor for overcoming drug resistance in cancer therapy(2006-present)
Yufeng An, Xinya Lv, Shidi Xu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 286, pp. 117268-117268
Closed Access
Novel pyrimidine-benzimidazole hybrids with antibacterial and antifungal properties and potential inhibition of SARS-CoV-2 main protease and spike glycoprotein
Sharuk L. Khan, Mayura Kale, Falak A. Siddiqui, et al.
Digital Chinese Medicine (2021) Vol. 4, Iss. 2, pp. 102-119
Open Access | Times Cited: 44
Design, synthesis, and tumor drug resistance reversal activity of novel hederagenin derivatives modified by nitrogen-containing heterocycles
Wentao Huang, Yingjie Wang, Si Xu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 232, pp. 114207-114207
Closed Access | Times Cited: 28
Insight on pyrimido[5,4-g]indolizine and pyrimido[4,5-c]pyrrolo[1,2-a]azepine systems as promising photosensitizers on malignant cells
Marilia Barreca, Angela Maria Ingarra, Maria Valeria Raimondi, et al.
European Journal of Medicinal Chemistry (2022) Vol. 237, pp. 114399-114399
Closed Access | Times Cited: 28
Novel pyrimidines as COX-2 selective inhibitors: synthesis, DFT analysis, molecular docking and dynamic simulation studies
Basavarajaiah Suliphuldevara Mathada, N. Jeelan Basha, Mohammad Javeed, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 4, pp. 1751-1764
Closed Access | Times Cited: 18
Expanding the potential of pyridine scaffold for targeted therapy of cancer: Biological activity, Molecular insights, and Structure-activity relationship
Nimmagadda Venkata Satya Sai Aishwarya, Gurubasavaraja Swamy Purawarga Matada, Rohit Pal, et al.
Journal of Molecular Structure (2024) Vol. 1321, pp. 139655-139655
Closed Access | Times Cited: 4
Nitrogen-boron eight-ring rigid cis/trans BODIPY-pyrimidine isomers for in vivo and in vitro fluorescence target recognition and evaluation of inhibitory activity
Tingyu Shao, Yuling Wang, Kaibo Hu, et al.
Dyes and Pigments (2022) Vol. 201, pp. 110204-110204
Closed Access | Times Cited: 21
1,2,4‐Triazole and benzimidazole fused dihydropyrimidine derivatives: Design, green synthesis, antibacterial, antitubercular, and antimalarial activities
Jaydeep A. Mokariya, Dhanji P. Rajani, Manish P. Patel
Archiv der Pharmazie (2022) Vol. 356, Iss. 4
Closed Access | Times Cited: 21
Biocatalytic Construction of Chiral Pyrrolidines and Indolines via Intramolecular C(sp3)–H Amination
Ziyang Qin, Shilong Gao, Yike Zou, et al.
ACS Central Science (2023) Vol. 9, Iss. 12, pp. 2333-2338
Open Access | Times Cited: 12
Biological Effects of Gyrophoric Acid and Other Lichen Derived Metabolites, on Cell Proliferation, Apoptosis and Cell Signaling pathways
Mahshid Mohammadi, Leila Bagheri, Amr A. Badreldin, et al.
Chemico-Biological Interactions (2021) Vol. 351, pp. 109768-109768
Open Access | Times Cited: 27
Novel pyrazolo[3,4-d]pyrimidines as potential anticancer agents: Synthesis, VEGFR-2 inhibition, and mechanisms of action
Zukela Ruzi, Khurshed Bozorov, Lifei Nie, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 156, pp. 113948-113948
Open Access | Times Cited: 19
Three Component One-Pot Synthesis and Antiproliferative Activity of New [1,2,4]Triazolo[4,3-a]pyrimidines
Manel Ben Hassen, Dhouha Msalbi, Badr Jismy, et al.
Molecules (2023) Vol. 28, Iss. 9, pp. 3917-3917
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top